{"entity":{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","aka":[],"tldr":"New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival.","summary":"Andrew Lassman is chief of neuro-oncology at Columbia University Irving Medical Center. He was the lead investigator and first author of the 2023 Neuro-Oncology report of INTELLANCE-1, the phase 3 trial of depatuxizumab mafodotin added to radiotherapy and temozolomide in EGFR-amplified newly diagnosed glioblastoma, which showed no overall survival benefit despite earlier promise. He leads several cooperative-group glioma trials.","asOf":"2026-09-18","links":[],"tags":["brain","trialist"],"related":[],"cancers":["glioblastoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["columbia-hicc"],"pathways":[],"terms":[],"trials":["intellance-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-andrew-lassman-neuro-oncol-2020","paper-andrew-lassman-j-clin-oncol-2022","paper-andrew-lassman-j-clin-oncol-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Neuro-Oncology, Columbia University Irving Medical Center","institutionId":"columbia-hicc","specialisms":["Glioblastoma","Antibody-drug conjugates","Neuro-oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lassman%5BAuthor%5D"}],"papers":[{"title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","journal":"Neuro-Oncology","year":2020,"url":"https://doi.org/10.1093/neuonc/noaa106","doi":"10.1093/neuonc/noaa106","note":"Europe PMC author record matched by affiliation (Herbert Irving Comprehensive Cancer Center, Columbia University); 999 citations on Europe PMC."},{"title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/jco.21.02314","doi":"10.1200/jco.21.02314","note":"Europe PMC author record matched by affiliation (Herbert Irving Comprehensive Cancer Center, Columbia University); 691 citations on Europe PMC."},{"title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/jco.23.01059","doi":"10.1200/jco.23.01059","note":"Europe PMC author record matched by affiliation (Herbert Irving Comprehensive Cancer Center, Columbia University); 389 citations on Europe PMC."}],"orcid":"0000-0001-7386-9928"},"route":"/people/andrew-lassman/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"institution":[{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/"}],"trial":[{"id":"intellance-1","kind":"trial","name":"INTELLANCE-1","route":"/trials/intellance-1/"}],"paper":[{"id":"paper-andrew-lassman-neuro-oncol-2020","kind":"paper","name":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","route":"/key-papers/paper-andrew-lassman-neuro-oncol-2020/"},{"id":"paper-andrew-lassman-j-clin-oncol-2023","kind":"paper","name":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2023/"},{"id":"paper-andrew-lassman-j-clin-oncol-2022","kind":"paper","name":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2022/"}]}}